Significance of molecular markers in survival prediction of oral squamous cell carcinoma

Head and Neck

Volumn 34, Issue 7, 2012, Pages 929-936

  Kim, Ki Yeol ^a   Li, ShengJin ^a   Cha, Jeong Dan ^a   Zhang, Xianglan ^a   Cha, In Ho ^a  

^a Yonsei University College of Dentistry   (South Korea)

Author keywords

Molecular markers; Oral squamous cell carcinoma; Significant factors; Survival prediction

Indexed keywords

CYCLOOXYGENASE 2; HUR PROTEIN; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NOMOGRAM; ORAL SURGERY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862892511     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21856     Document Type: Article

References (36)

1. Sudbo J, Reith A. The evolution of predictive oncology and molecularbased therapy for oral cancer prevention. Int J Cancer 2005;115:339-345. (Pubitemid 40663735)
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29. (Pubitemid 29409471)
3. Epstein JB, Sciubba J, Silverman S Jr, Sroussi HY. Utility of toluidine blue in oral premalignant lesions and squamous cell carcinoma: continuing research and implications for clinical practice. Head Neck 2007;29: 948-958.
4. Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY, Yun PY. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006;35: 1005-1010. (Pubitemid 44615441)
5. Stephenson AJ, Smith A, Kattan MW, et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005;104: 290-298. (Pubitemid 40993255)
6. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10:5464-5471. (Pubitemid 39100484)
7. Yuen PW, Man M, Lam KY, Kwong YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 2002;55: 58-60. (Pubitemid 34081683)
8. Lo Muzio L, Falaschini S, Farina A, et al. Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. Oncol Res 2005;15:249-255. (Pubitemid 41415103)
9. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819. (Pubitemid 29493956)
10. Raju B, Mehrotra R, Oijordsbakken G, Al-Sharabi AK, Vasstrand EN, Ibrahim SO. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathological parameters. Anticancer Res 2005;25:4699-4706. (Pubitemid 41729533)
11. Shah NG, Trivedi TI, Tankshali RA, et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck 2009;31:1544-1556.
12. Galli P, Cadoni G, Volante M, et al. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer 2009;9:137.
13. Goulart Filho JA, Nonaka CF, da Costa Miguel MC, de Almeida Freitas R, Galvão HC. Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. Am J Otolaryngol 2009;30:89-94.
14. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol 2009;45: 647-653.
15. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003;88:887-894. (Pubitemid 36520876)
16. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-564. (Pubitemid 43923666)
17. Jeng YM, Chang CC, Hu FC, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 2008;48:1118-1127.
18. Li L, Xu H, Spaulding BO, et al. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol 2008;39:1205-1211.
19. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008;14:1701-1706. (Pubitemid 351469454)
20. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma. Expert Rev Mol Diagn 2008;8:557-558.
21. Li S, Cha J, Kim J, et al. Insulin-like growth factor II mRNA-binding protein 3: a novel prognostic biomarker for oral squamous cell carcinoma. Head Neck 2011;33:368-374.
22. Yamac D, Celenkoglu G, Coskun U, et al. Prognostic importance of COX- 2 expression in patients with colorectal cancer. Pathol Res Pract 2005; 201:497-502. (Pubitemid 41131390)
23. Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 2008;204:241-249. (Pubitemid 351377530)
24. Takatori H, Natsugoe S, Okumura H, et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 2008;34:397-402. (Pubitemid 351381291)
25. Zafirellis K, Agrogiannis G, Zachaki A. Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer. APMIS 2008;116:912-922.
26. Hermanova M, Karasek P, Nenutil R, et al. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas 2009;38: 565-571.
27. Cha JD, Li S, Cha IH. Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma. Head Neck 2011;33:627-637.
28. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771. (Pubitemid 28259189)
29. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-1507. (Pubitemid 29220858)
30. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005-7012.
31. Rouzier R, Preti M, Haddad B, Martin M, Micheletti L, Paniel BJ. Development and validation of a nomogram for predicting outcome of patients with vulvar cancer. Obstet Gynecol 2006;107:672-677.
32. Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol 2009;20:955-960.
33. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007;25: 1316-1322. (Pubitemid 46706877)
34. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005;23:8331-8339.
35. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-smallcell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23:175-183. (Pubitemid 41702636)
36. Bianco FJ Jr. Nomograms and medicine. Eur Urol 2006;50:884-886.